Literature DB >> 11011123

p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens from non-transition and transition zones.

H Takayama1, M Shin, N Nonomura, A Okuyama, K Aozasa.   

Abstract

Prostatic intraepithelial neoplasia (PIN) is characterized by intraluminal proliferation of epithelial cells and is divided into high-grade (HGPIN) and low-grade (LGPIN) lesions. HGPIN is regarded as the most likely precursor of prostatic cancer (PCA). Microdissected DNA selectively extracted from paraffin-embedded sections of 27 cases with PCA were analyzed for p53 mutation in exons 5 - 8 by single-strand conformation polymorphism of polymerase chain reaction-amplified DNA fragments (PCR-SSCP) followed by direct sequencing. These patients received total prostatectomy (27 cases). After a review of histologic sections, DNA was extracted from 193 locations; 111 lesions from 27 cases with HGPIN (75 lesions from non-transition zone and 36 from transition zone), 55 lesions from 27 cases with PCA (30 lesions from non-transition zone and 25 from transition zone), and 27 from 27 benign glands. Analysis revealed 27 mutations of the p53 gene in 24 lesions from 12 cases. Benign glands adjoining PIN and / or PCA had no mutations. All mutations were point mutations: 17 missense, 7 silent, and 2 nonsense. Mutations were detected in 6 cases (22.2%) or 13 of 111 lesions (11.7%) with HGPIN and 8 cases (29.6%) or 11 of 55 lesions (20.0%) with PCA. In a given case, HGPIN and PCA lesions had different p53 mutations from each other, suggesting multiclonal development of prostatic precancerous lesions. The frequency of p53 mutation of PCA was significantly higher in the non-transition zone (33.3%) than in the transition zone (4%), and higher in the stage T3 cases (30.3%) than in the stage T2 cases (4.5%, 1 of 22 lesions) (both P < 0.05). Frequency of p53 mutation of PIN in the non-transition zone (14.7%) was higher than that in the transition zone (5.6%), although the difference was not significant. The frequency rate of p53 mutation in HGPIN close to PCA ( </= 2 mm) was significantly higher (24%) than that in HGPIN lesions > 2 mm from PCA (3%). All these findings indicate that the p53 gene mutations are involved in prostatic carcinogenesis and explain why the non-transition zone is the predominant site of PCA.

Entities:  

Mesh:

Year:  2000        PMID: 11011123      PMCID: PMC5926450          DOI: 10.1111/j.1349-7006.2000.tb01038.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  28 in total

1.  Origins of prostate cancer.

Authors:  R Montironi; D G Bostwick; H Bonkhoff; A T Cockett; B Helpap; P Troncoso; D Waters
Journal:  Cancer       Date:  1996-07-15       Impact factor: 6.860

2.  Extent and zonal distribution of prostatic intraepithelial neoplasia in patients with prostatic carcinoma in Japan: analysis of whole-mounted prostatectomy specimens.

Authors:  M Shin; H Takayama; N Nonomura; A Wakatsuki; A Okuyama; K Aozasa
Journal:  Prostate       Date:  2000-02-01       Impact factor: 4.104

3.  The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma.

Authors:  J Qian; P Wollan; D G Bostwick
Journal:  Hum Pathol       Date:  1997-02       Impact factor: 3.466

4.  Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines.

Authors:  Y Yasunaga; H Nakanishi; N Naka; T Miki; T Tsujimura; H Itatani; A Okuyama; K Aozasa
Journal:  Lab Invest       Date:  1997-12       Impact factor: 5.662

5.  Prostatic intraepithelial neoplasia in surgical resections: relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate.

Authors:  F J Skjørten; A Berner; S Harvei; T E Robsahm; S Tretli
Journal:  Cancer       Date:  1997-03-15       Impact factor: 6.860

6.  Staging of prostate cancer.

Authors:  D G Bostwick; R P Myers; J E Oesterling
Journal:  Semin Surg Oncol       Date:  1994 Jan-Feb

7.  Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization.

Authors:  J Qian; D G Bostwick; S Takahashi; T J Borell; J F Herath; M M Lieber; R B Jenkins
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

8.  TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue.

Authors:  A Berner; G Geitvik; F Karlsen; S D Fosså; J M Nesland; A L Børresen
Journal:  J Pathol       Date:  1995-07       Impact factor: 7.996

9.  Prostatic intra-epithelial neoplasia and early invasion in prostate cancer.

Authors:  D G Bostwick; M K Brawer
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

10.  p53 gene mutations in human prostate cancers in Japan: different mutation spectra between Japan and western countries.

Authors:  M Watanabe; T Ushijima; H Kakiuchi; T Shiraishi; R Yatani; J Shimazaki; T Kotake; T Sugimura; M Nagao
Journal:  Jpn J Cancer Res       Date:  1994-09
View more
  2 in total

1.  Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation.

Authors:  Thirupandiyur S Udayakumar; Paul Hachem; Mansoor M Ahmed; Sudhir Agrawal; Alan Pollack
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

2.  Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.

Authors:  Zhuo Zhang; Mao Li; Hui Wang; Sudhir Agrawal; Ruiwen Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-16       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.